Related Experiment Video

Updated: Mar 1, 2026

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry
13:13

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

Published on: September 23, 2014

30.9K

HGF/Met Axis in Heart Function and Cardioprotection

Simona Gallo1, Valentina Sala2,3, Stefano Gatti4

  • 1Department of Oncology, University of Turin, Corso Massimo D'Azeglio 52, 10126 Turin, Italy. simona.gallo@unito.it.

Biomedicines
|May 27, 2017
PubMed

Insights

Hepatocyte growth factor (HGF) and its receptor Met are crucial for heart health, offering protection against injury and aiding regeneration. Understanding HGF/Met signaling is vital for treating cardiac diseases and considering potential side effects of cancer therapies.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Oncology

Background:

  • Hepatocyte growth factor (HGF) and its receptor tyrosine kinase (Met) are integral to myocardial function.
  • HGF/Met signaling regulates cardiomyocyte proliferation, differentiation, homeostasis, and protection from oxidative stress.
  • The role of HGF/Met in both physiological and pathological cardiac conditions necessitates careful consideration, especially regarding Met-targeted cancer therapies.

Purpose of the Study:

  • To review the multifaceted roles of HGF/Met signaling in cardiac physiology and pathology.
  • To explore the cardioprotective mechanisms of HGF in injured hearts.
  • To discuss the prognostic value of HGF and its therapeutic potential in cardiovascular diseases.

Main Methods:

  • Literature review and synthesis of existing research on HGF/Met signaling in the heart.
  • Analysis of HGF's functions in cardiac development, homeostasis, injury, and regeneration.
  • Examination of HGF's role as a prognostic marker and therapeutic target.

Main Results:

  • HGF/Met signaling is essential for cardiomyocyte development and adult heart homeostasis.
  • In injured hearts, HGF promotes cardiomyocyte survival, angiogenesis, fibrosis inhibition, and anti-inflammatory effects.
  • Elevated HGF levels may serve as a prognostic marker for cardiac disease severity.

Conclusions:

  • HGF/Met signaling is a critical regulator of myocardial function, offering significant cardioprotection.
  • HGF has potential as a therapeutic agent for various cardiac conditions.
  • The cardiotoxicity of Met-targeted cancer therapies warrants further investigation.

Keywords:
Met tyrosine kinase receptorangiogenesiscardiac regenerationcardioprotectioncardiotoxicityfibrosisheart developmenthepatocyte growth factorinflammationmyocardial infarction

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K
Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells05:38

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Published on: February 12, 2021

4.8K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551